Jonathan Wynn is a Cardiology physician. OpenAlex indexes 19 publications with 296 citations (h-index 9); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
210 Westchester Ave
White Plains, NY 106042901
Telephone
914-305-2700Registry record last updated 4 Sept 2015.
Clinical trials
- Inter-Brain Synchrony in Schizophrenia
Sponsor: University of California, Los Angeles
- Neuroplasticity in TBI and Schizophrenia
Sponsor: VA Office of Research and Development
- Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
Sponsor: VA Greater Los Angeles Healthcare System
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
71.7%Statin20.4%Atorvastatin Calcium66%Simvastatin24%Rosuvastatin Calcium10%Part D≥86 patientsBeta blocker13.1%Metoprolol Succinate43%Carvedilol20%Metoprolol Tartrate19%Atenolol10%Labetalol Hcl9%Part D<11 patients+ 11 more classes in this area
Blood & clotting
13.1%Factor Xa inhibitor8.3%Eliquis75%Xarelto25%Part D≥36 patientsP2Y12 inhibitor3.7%Clopidogrel100%Part D≥27 patients+ 1 more class in this area
Metabolism & gastrointestinal
9.2%Biguanide (metformin)3.3%Metformin Hcl55%Metformin Hcl Er45%Part D≥13 patientsPotassium supplement2.2%Potassium Chloride58%Klor-Con M2042%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- REDISTRIBUTION OF CONNEXIN 43 BY cAMP: A MECHANISM FOR GROWTH CONTROL IN ADRENAL CELLS
Endocrine Research
2002 - CHANGES IN CONDITIONING AND SUB-MAXIMAL VENTILATORY PARAMETERS SUBSEQUENT TO PARTICIPATION IN AN OUTPATIENT PULMONARY REHABILITATION PROGRAM
Journal of Cardiopulmonary Rehabilitation
1994
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”